Neomycin, a Gram-negative-specific antibiotic, blocks this CXCL1-PMN-MDSC axis, validating the gut-liver-CCA interplay linking microbial imbalance, barrier integrity, and antitumor immunity (19). The gene discussed is CXCL1; the disease is cholangiocarcinoma.